Objective: To assess the possible role of human Urotensin-II (hU-II), a vaso active peptide, in the pathophysiology of preeclampsia-eclampsia prospectively. Study design: Sixty subjects, 30 with a diagnosis of preecla...Objective: To assess the possible role of human Urotensin-II (hU-II), a vaso active peptide, in the pathophysiology of preeclampsia-eclampsia prospectively. Study design: Sixty subjects, 30 with a diagnosis of preeclampsia-eclampsia (g roup I) and 30 control subjects (group II), who had been admitted between Januar y, 2002 and December, 2002, were taken into the study. Patients in group I had a n increase in blood pressure after 28th week of gestation, without any history o f hypertensive disease and/or preeclampsia or eclampsia. hU-II levels were asse ssed using a radioimmunoassay method. Results: No statistically significant diff erence in terms of age, gestational age, gravidity, abortion and parity was dete cted among groups (P >0.05). Plasma hU-II levels in the preeclampsia-eclampsia and control groups were 10.11 ±5.94 pg/mL and 3.93 ±1.73 pg/mL, respectively. Difference between plasma hU-II levels of the two groups was found to be stati stically significant (P < .00001). Also there was correlation between hU-II lev els and mean arterial pressures in both groups (r = 0.73, P < 0.0001 and r = 0.7 2, P < 0.0001 for groups I and II, respectively). Conclusion: Results of our stu dy strongly suggest an important role for hU-II in the pathophysiology of preec lampsia-eclampsia. Further studies concerning placenta and cord blood samples w ill more clearly elucidate the role of Urotensin-II in the pathogenesis of pree clampsia-eclampsia, and its feto-maternal effects.展开更多
文摘Objective: To assess the possible role of human Urotensin-II (hU-II), a vaso active peptide, in the pathophysiology of preeclampsia-eclampsia prospectively. Study design: Sixty subjects, 30 with a diagnosis of preeclampsia-eclampsia (g roup I) and 30 control subjects (group II), who had been admitted between Januar y, 2002 and December, 2002, were taken into the study. Patients in group I had a n increase in blood pressure after 28th week of gestation, without any history o f hypertensive disease and/or preeclampsia or eclampsia. hU-II levels were asse ssed using a radioimmunoassay method. Results: No statistically significant diff erence in terms of age, gestational age, gravidity, abortion and parity was dete cted among groups (P >0.05). Plasma hU-II levels in the preeclampsia-eclampsia and control groups were 10.11 ±5.94 pg/mL and 3.93 ±1.73 pg/mL, respectively. Difference between plasma hU-II levels of the two groups was found to be stati stically significant (P < .00001). Also there was correlation between hU-II lev els and mean arterial pressures in both groups (r = 0.73, P < 0.0001 and r = 0.7 2, P < 0.0001 for groups I and II, respectively). Conclusion: Results of our stu dy strongly suggest an important role for hU-II in the pathophysiology of preec lampsia-eclampsia. Further studies concerning placenta and cord blood samples w ill more clearly elucidate the role of Urotensin-II in the pathogenesis of pree clampsia-eclampsia, and its feto-maternal effects.
